Cameron Kurowski, MD
Family Medicine · Candler, NCNPI 1174584437
Payments from drug & device makers
Across 110 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$218
- Pfizer$189
- GSK$180
- AbbVie$169
- Novo Nordisk$134
- Ironwood Pharmaceuticals, Inc$108
- plus $812 from 23 others
What the payments were for
- Food & beverage$1,810100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 13 | $218 |
| Pfizer | 10 | $189 |
| GSK | 10 | $180 |
| AbbVie(2 entities) | 10 | $169 |
| Novo Nordisk | 10 | $134 |
| Ironwood Pharmaceuticals, Inc | 7 | $108 |
| AstraZeneca | 5 | $89 |
| Corcept Therapeutics | 5 | $87 |
| Abbott | 5 | $86 |
| Radius Health, Inc. | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Exact Sciences | 3 | $50 |
| Johnson & Johnson | 3 | $46 |
| Inari Medical, Inc. | 2 | $43 |
| Boehringer Ingelheim | 3 | $42 |
| Lilly USA, LLC | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Medtronic | 1 | $18 |
| Novartis | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Bayer | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Merck | 1 | $11 |
How this compares
$1,810 in reported general payments places this provider in the 75th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $105,009 |
| EliquisApixaban | 103 | $83,055 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $51,061 |
| TrulicityDulaglutide | 41 | $48,447 |
| JardianceEmpagliflozin | 25 | $39,648 |
| Abilify MaintenaAripiprazole | 12 | $33,738 |
| BelsomraSuvorexant | 49 | $20,655 |
| VraylarCariprazine Hcl | 12 | $16,321 |
| XareltoRivaroxaban | 17 | $15,834 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $14,882 |
| Emgality PenGalcanezumab-Gnlm | 18 | $12,102 |
| LinzessLinaclotide | 22 | $11,236 |
| OxycontinOxycodone Hcl | 12 | $10,565 |
| Repatha SureclickEvolocumab | 15 | $8,465 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 218 | $7,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $134 | $105,00979 claims |
| PfizerEliquis | $189 | $83,055103 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta, Arnuity Ellipta | $180 | $67,186128 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat | $42 | $52,66050 claims |
| Lilly USA, LLCTrulicity | $38 | $48,44741 claims |
| AbbVieVraylar, Linzess, Synthroid | $169 | $29,21458 claims |
| MerckBelsomra | $11 | $20,65549 claims |
| Johnson & JohnsonXarelto | $46 | $15,83417 claims |
| AstraZenecaFarxiga, Symbicort | $89 | $14,33836 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $50 | $5,88411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Candler
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.